Cargando…

Driving Immune Responses in the Ovarian Tumor Microenvironment

Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Franklin, Cole, Christopher B., Annunziata, Christina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843421/
https://www.ncbi.nlm.nih.gov/pubmed/33520713
http://dx.doi.org/10.3389/fonc.2020.604084
_version_ 1783644138076372992
author Ning, Franklin
Cole, Christopher B.
Annunziata, Christina M.
author_facet Ning, Franklin
Cole, Christopher B.
Annunziata, Christina M.
author_sort Ning, Franklin
collection PubMed
description Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chemo-resistance. Recent approvals for bevacizumab and poly (ADP-ribose) polymerase inhibitors have improved treatment options but effective treatments are still limited in the recurrent setting. Immunotherapy has seen significant success in hematological and solid malignancies. However, effectiveness has been limited in ovarian cancer. This may be due to a highly immunosuppressive tumor microenvironment and a lack of tumor-specific antigens. Certain immune cell subsets, such as regulatory T cells and tumor-associated macrophages, have been implicated in ovarian cancer. Consequently, therapies augmenting the immune response, such as immune checkpoint inhibitors and dendritic cell vaccines, may be unable to properly enact their effector functions. A better understanding of the various interactions among immune cell subsets in the peritoneal microenvironment is necessary to develop efficacious therapies. This review will discuss various cell subsets in the ovarian tumor microenvironment, current immunotherapy modalities to target or augment these immune subsets, and treatment challenges.
format Online
Article
Text
id pubmed-7843421
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78434212021-01-30 Driving Immune Responses in the Ovarian Tumor Microenvironment Ning, Franklin Cole, Christopher B. Annunziata, Christina M. Front Oncol Oncology Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence due to late stage diagnoses and acquired chemo-resistance. Recent approvals for bevacizumab and poly (ADP-ribose) polymerase inhibitors have improved treatment options but effective treatments are still limited in the recurrent setting. Immunotherapy has seen significant success in hematological and solid malignancies. However, effectiveness has been limited in ovarian cancer. This may be due to a highly immunosuppressive tumor microenvironment and a lack of tumor-specific antigens. Certain immune cell subsets, such as regulatory T cells and tumor-associated macrophages, have been implicated in ovarian cancer. Consequently, therapies augmenting the immune response, such as immune checkpoint inhibitors and dendritic cell vaccines, may be unable to properly enact their effector functions. A better understanding of the various interactions among immune cell subsets in the peritoneal microenvironment is necessary to develop efficacious therapies. This review will discuss various cell subsets in the ovarian tumor microenvironment, current immunotherapy modalities to target or augment these immune subsets, and treatment challenges. Frontiers Media S.A. 2021-01-15 /pmc/articles/PMC7843421/ /pubmed/33520713 http://dx.doi.org/10.3389/fonc.2020.604084 Text en Copyright © 2021 Ning, Cole and Annunziata http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ning, Franklin
Cole, Christopher B.
Annunziata, Christina M.
Driving Immune Responses in the Ovarian Tumor Microenvironment
title Driving Immune Responses in the Ovarian Tumor Microenvironment
title_full Driving Immune Responses in the Ovarian Tumor Microenvironment
title_fullStr Driving Immune Responses in the Ovarian Tumor Microenvironment
title_full_unstemmed Driving Immune Responses in the Ovarian Tumor Microenvironment
title_short Driving Immune Responses in the Ovarian Tumor Microenvironment
title_sort driving immune responses in the ovarian tumor microenvironment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843421/
https://www.ncbi.nlm.nih.gov/pubmed/33520713
http://dx.doi.org/10.3389/fonc.2020.604084
work_keys_str_mv AT ningfranklin drivingimmuneresponsesintheovariantumormicroenvironment
AT colechristopherb drivingimmuneresponsesintheovariantumormicroenvironment
AT annunziatachristinam drivingimmuneresponsesintheovariantumormicroenvironment